Suppr超能文献

强化氨基糖苷类/头孢菌素治疗在氟喹诺酮类耐药细菌性角膜炎中的一线治疗价值。

The Value of Fortified Aminoglycoside/Cephalosporin Treatment as First-Line Treatment and in Fluoroquinolone-Resistant Bacterial Keratitis.

机构信息

Hacettepe University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey

Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey

出版信息

Turk J Ophthalmol. 2020 Oct 30;50(5):258-263. doi: 10.4274/tjo.galenos.2020.37346.

Abstract

OBJECTIVES

Topical application of fluoroquinolone antibiotics is thought to be as effective as fortified antibiotics. The aim of this study was to evaluate the efficacy of fluoroquinolones as an alternative to fortified antibiotic therapies.

MATERIALS AND METHODS

The medical records of 31 patients who were hospitalized in our department due to bacterial keratitis were retrospectively reviewed. Fluoroquinolone was started as the first treatment for 20 (64.5%) patients and upon no response fortified antibiotic was initiated, and 11 (35.5%) patients were started with fortified treatment. Cultures and smears were recorded before treatment. Lesions were evaluated as superficial or deep according to their depth. Treatment response was evaluated based on reduction of infiltrate depth and size, change in visual acuity, and regression of hypopyon.

RESULTS

Central, paracentral, and peripheral location were detected in 9 (29.0%), 10 (32.2%) and 12 (38.7%) eyes, respectively. According to lesion depth, 15 (48.3%) were deep and 16 (51.6%) were superficial. Response of superficial lesions was found to be statistically earlier (p=0.037). Culture was positive in 9 (29.0%) eyes. The initial best corrected visual acuity (BCVA) was 0.5±0.7 logMAR (-0.1-2.3) and 0.3±0.3 logMAR (-0.1-0.9) after treatment. Treatment response showed moderate but statistically nonsignificant correlation with time to treatment initiation and initial BCVA (r=0.527, p=0.184; r=0.517, p=0.120).

CONCLUSION

Although fluoroquinolones are the first choice for the treatment of bacterial keratitis, fortified antibiotics have been shown to be effective in patients who do not respond to treatment. Fortified therapy should be kept in mind in the treatment of bacterial keratitis.

摘要

目的

局部应用氟喹诺酮类抗生素被认为与强化抗生素一样有效。本研究旨在评估氟喹诺酮类药物替代强化抗生素治疗的效果。

材料和方法

回顾性分析因细菌性角膜炎在我科住院的 31 例患者的病历。20 例(64.5%)患者开始使用氟喹诺酮类药物作为一线治疗,无反应时开始强化抗生素治疗,11 例(35.5%)患者开始强化治疗。记录治疗前的培养物和涂片。根据病变深度将病变分为浅层或深层。根据浸润深度和大小的减少、视力的变化和前房积脓的消退来评估治疗反应。

结果

9 只眼(29.0%)、10 只眼(32.2%)和 12 只眼(38.7%)分别位于中央、旁中央和周边位置。根据病变深度,15 只眼(48.3%)为深层,16 只眼(51.6%)为浅层。浅层病变的反应明显更早(p=0.037)。9 只眼(29.0%)培养阳性。初始最佳矫正视力(BCVA)为 0.5±0.7 logMAR(-0.1-2.3),治疗后为 0.3±0.3 logMAR(-0.1-0.9)。治疗反应与治疗开始时间和初始 BCVA 呈中度但无统计学意义的相关性(r=0.527,p=0.184;r=0.517,p=0.120)。

结论

虽然氟喹诺酮类药物是细菌性角膜炎的首选治疗药物,但强化抗生素对治疗无反应的患者也有效。在细菌性角膜炎的治疗中应考虑强化治疗。

相似文献

2
The combination of topical ceftazidime and aminoglycosides in the treatment of refractory pseudomonal keratitis.
Graefes Arch Clin Exp Ophthalmol. 1999 Mar;237(3):177-80. doi: 10.1007/s004170050215.
4
Bacterial keratitis in a tertiary hospital in São Paulo: a 21-year review of the epidemiological, laboratory, and clinical data.
Braz J Infect Dis. 2023 Sep-Oct;27(5):102809. doi: 10.1016/j.bjid.2023.102809. Epub 2023 Oct 6.
5
Safety and efficacy of fortified antibiotics and fluoroquinolones for the treatment of bacterial keratitis: A meta-analysis.
J Fr Ophtalmol. 2024 May;47(5):103940. doi: 10.1016/j.jfo.2023.01.046. Epub 2023 Sep 22.
7
Methicillin-Resistant Staphylococcus aureus Keratitis: Initial Treatment, Risk Factors, Clinical Features, and Treatment Outcomes.
Am J Ophthalmol. 2020 Jun;214:119-126. doi: 10.1016/j.ajo.2020.03.017. Epub 2020 Mar 21.
9
Fluoroquinolones in the treatment of bacterial keratitis.
Am J Ophthalmol. 1996 Jun;121(6):712-5. doi: 10.1016/s0002-9394(14)70641-5.

引用本文的文献

1
Resistance trend in bacteria isolated from corneal ulcers: A retrospective analysis from Pakistan.
PLoS One. 2025 Jun 5;20(6):e0325157. doi: 10.1371/journal.pone.0325157. eCollection 2025.
2
A comparison of antimicrobial regimen outcomes and antibiogram development in microbial keratitis: a prospective cohort study in Alexandria, Egypt.
Graefes Arch Clin Exp Ophthalmol. 2024 Jun;262(6):1865-1882. doi: 10.1007/s00417-023-06362-0. Epub 2024 Jan 19.
4
Ocular Surface Infection Mediated Molecular Stress Responses: A Review.
Int J Mol Sci. 2022 Mar 14;23(6):3111. doi: 10.3390/ijms23063111.

本文引用的文献

1
Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity.
Pharmacy (Basel). 2019 Jul 29;7(3):103. doi: 10.3390/pharmacy7030103.
2
Contact Lens-Associated Microbial Keratitis in a Tertiary Eye Care Center in Turkey.
Eye Contact Lens. 2020 Mar;46(2):110-115. doi: 10.1097/ICL.0000000000000617.
3
The persistent dilemma of microbial keratitis: Global burden, diagnosis, and antimicrobial resistance.
Surv Ophthalmol. 2019 May-Jun;64(3):255-271. doi: 10.1016/j.survophthal.2018.12.003. Epub 2018 Dec 24.
4
Bacterial Keratitis Preferred Practice Pattern®.
Ophthalmology. 2019 Jan;126(1):P1-P55. doi: 10.1016/j.ophtha.2018.10.018. Epub 2018 Oct 23.
5
Effect of Mucoadhesive Polymeric Formulation on Corneal Permeation of Fluoroquinolones.
J Ocul Pharmacol Ther. 2018 Oct;34(8):570-578. doi: 10.1089/jop.2018.0059. Epub 2018 Aug 23.
6
Empirical treatment of bacterial keratitis: an international survey of corneal specialists.
BMJ Open Ophthalmol. 2017 Aug;2(1). doi: 10.1136/bmjophth-2016-000047. Epub 2017 Aug 16.
7
Infectious keratitis and orthokeratology lens use: a systematic review.
Infection. 2017 Dec;45(6):727-735. doi: 10.1007/s15010-017-1023-2. Epub 2017 May 22.
8
Fluoroquinolone antimicrobial drugs.
CMAJ. 2017 May 1;189(17):E638. doi: 10.1503/cmaj.160938.
9
Pathogenesis of microbial keratitis.
Microb Pathog. 2017 Mar;104:97-109. doi: 10.1016/j.micpath.2016.12.013. Epub 2016 Dec 18.
10
Polymicrobial Infection of the Cornea Due to Contact Lens Wear.
Turk J Ophthalmol. 2016 Apr;46(2):83-86. doi: 10.4274/tjo.03779. Epub 2016 Apr 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验